Zacks Research cut shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) from a strong-buy rating to a hold rating in a research note published on Thursday,Zacks reports.
A number of other research firms also recently issued reports on ARCT. Leerink Partners increased their price objective on Arcturus Therapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. BTIG Research lowered their price target on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Thursday, September 24th. Roth Capital restated a “buy” rating and issued a $41.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Finally, Wall Street Zen raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.
Check Out Our Latest Research Report on Arcturus Therapeutics
Arcturus Therapeutics Stock Performance
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.43. Arcturus Therapeutics had a negative return on equity of 46.79% and a negative net margin of 285.92%. The company had revenue of $18.30 million during the quarter, compared to analysts’ expectations of $8.00 million. Sell-side analysts forecast that Arcturus Therapeutics will post -2.94 earnings per share for the current year.
Institutional Trading of Arcturus Therapeutics
A number of large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of Arcturus Therapeutics during the third quarter valued at approximately $415,000. Entropy Technologies LP purchased a new stake in Arcturus Therapeutics in the third quarter worth approximately $767,000. Empowered Funds LLC purchased a new stake in Arcturus Therapeutics in the third quarter worth approximately $491,000. Tocqueville Asset Management L.P. bought a new stake in Arcturus Therapeutics in the 3rd quarter worth approximately $144,000. Finally, Kovack Advisors Inc. bought a new stake in Arcturus Therapeutics in the 3rd quarter worth approximately $144,000. 94.54% of the stock is currently owned by institutional investors.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.
Read More
- Five stocks we like better than Arcturus Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
